ONO7475 manufacturers
- ONO-7475
-
- $57.00
-
2026-04-21
- CAS:1646839-59-9
- Purity: 98.74%
- Supply Ability: 10g
|
| | ONO7475 Basic information |
| Product Name: | ONO7475 | | Synonyms: | ONO7475;3-Quinolinecarboxamide, N-[5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-;N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide;lung,tumor,leukemia,inhibit,solid,Trk Receptor,tolerant,cancer,Mer,Tropomyosin related kinase receptor,NSCLC,TAM Receptor,EGFR,ONO 7475,Tyro3,advanced,ONO7475,mutunt,Inhibitor,Axl,TKI,acute,ONO-7475,metastatic;N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide , Tamnorzatinib;ONO-7475, 10 mM in DMSO;Tamnorzatinib (ONO-7475);ONO-7475 ，S8933 | | CAS: | 1646839-59-9 | | MF: | C32H26N4O6 | | MW: | 562.57 | | EINECS: | | | Product Categories: | | | Mol File: | 1646839-59-9.mol |  |
| | ONO7475 Chemical Properties |
| Boiling point | 804.0±65.0 °C(Predicted) | | density | 1.43±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml | | form | A crystalline solid | | pka | 8.50±0.20(Predicted) | | color | Light yellow to yellow |
| | ONO7475 Usage And Synthesis |
| Uses | Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC). | | in vivo | Tamnorzatinib (oral gavage; 10 mg/kg or combines with 5 mg/kg Osimertinib; 29 days) treatment alone has little effect on the tumor growth. Besides, Osimertinib alone causes tumor regression within one week, but the tumors reappear within three weeks. The combined initial treatment causes tumor regression and the size of tumors is maintained for 4 weeks. No apparent adverse events, including weight loss are observed during these treatments[1]. | Animal Model: | Mouse CDX model using high-AXL-expressing PC-9KGR cells (exon 19 deletion and the exon21-T790M mutation in EGFR)[1] | | Dosage: | 10 mg/kg; once daily; 19 days | | Administration: | oral gavage | | Result: | Had little effects alone, but combined treatments significantly decreased tumor volume without reappear. |
| | IC 50 | TrkA; Axl; Tyro3; Mer | | References | [1] Okura N, et al. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment inEGFR-Mutated Non-Small Lung Cancer.Clin Cancer Res.2020 Jan 17. DOI:10.1158/1078-0432.CCR-19-2321
[2] Ruvolo PP, et al. Anexelekto/MER tyrosine kinaseinhibitorONO-7475arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.Haematologica.2017 Dec;102(12):2048-2057. DOI:10.3324/haematol.2017.168856 |
| | ONO7475 Preparation Products And Raw materials |
|